Skip to main content
Affluent Medical logo

Affluent Medical — Investor Relations & Filings

Ticker · AFME ISIN · FR0013333077 LEI · 969500N30CO4B5N2GN67 PA Manufacturing
Open in API
Filings indexed 275 across all filing types
Latest filing 2025-09-30 Earnings Release
Country FR France
Listing PA AFME

About Affluent Medical

https://www.affluentmedical.com

Affluent Medical is a clinical-stage medical technology company that develops innovative, minimally invasive implants designed to restore essential physiological functions. The company's activities are concentrated in two primary therapeutic areas: structural heart disease and urology. It specifically addresses severe mitral valve insufficiency and urinary incontinence. The product pipeline, currently in clinical development, features three key devices: Kalios™, an adjustable annuloplasty ring for mitral valve repair; Epygon™, a biomimetic mitral valve for replacement procedures; and Artus™, an electronic artificial urinary sphincter for treating urinary incontinence. Affluent Medical's technologies are engineered to be adjustable and biomimetic, allowing for implantation via minimally invasive surgery and adaptation to both the patient's anatomy and the progression of their pathology.

Recent filings

Filing Released Lang Actions
Affluent Medical: H1 2025 RESULTS: Affluent Medical took major new and transformative steps during the first half of 2025
Earnings Release Classification · 100% confidence The document is an announcement of the company's H1 2025 financial results. It provides a summary of key highlights, operational milestones, and financial data, but explicitly states at the end that the 'full financial statements are available on our website' and provides a link to the '2025 interim financial report' PDF. Because the document is an announcement summarizing results and directing the reader to the full report, it falls under the Report Publication Announcement (RPA) category. H1 2025
2025-09-30 English
Affluent Medical : Affluent Medical announces that the clinical results of the Artus robotic urinary sphincter were presented at the international conferences of the UAA and the ICS
Regulatory Filings Classification · 100% confidence The document is a press release issued by Affluent Medical regarding the presentation of clinical trial results for their 'Artus' robotic urinary sphincter at international medical conferences. It does not fit into financial reporting categories like 10-K, IR, or ER, nor is it a regulatory filing or a report publication announcement. As it is a general corporate announcement regarding company operations and clinical progress, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate news.
2025-09-29 English
Affluent Medical : Affluent Medical annonce la présentation des résultats cliniques du sphincter urinaire robotique Artus, aux congrès internationaux de l’UAA et de l’ICS
Regulatory Filings Classification · 100% confidence The document is a press release issued by Affluent Medical announcing the presentation of clinical results for their 'Artus' robotic urinary sphincter at international medical congresses (UAA and ICS). It details the clinical findings, the safety profile, and the progress of the clinical trial (DRY study). It does not constitute a formal financial report, audit, or regulatory filing, but rather a corporate communication regarding operational and clinical progress. As it is a general regulatory announcement that does not fit into specific categories like earnings or M&A, it is classified as a Regulatory Filing (RNS).
2025-09-29 French
Affluent Medical : Affluent Medical announces that the clinical results of the Artus robotic urinary sphincter were presented at the international conferences of the UAA and the ICS
Regulatory Filings Classification · 100% confidence The document is a press release issued by Affluent Medical regarding the presentation of clinical trial results for their 'Artus' medical device at international conferences. It is disseminated via a regulatory news service (EQS Group) and contains corporate news rather than a formal financial report, audit, or proxy statement. As it is a general regulatory announcement that does not fit into specific categories like earnings releases or M&A, it is classified as a Regulatory Filing (RNS).
2025-09-29 English
Affluent Medical : Bilan semestriel du contrat de liquidité contracté avec la banque Rothschild Martin Maurel
Transaction in Own Shares Classification · 98% confidence The document is titled "Bilan semestriel du contrat de liquidité contracté avec la banque Rothschild Martin Maurel" (Semi-annual balance sheet of the liquidity contract with Rothschild Martin Maurel bank). It details the status of shares and cash held under a liquidity contract as of June 30, 2025, and provides transaction summaries (purchases and sales) for the period January 1, 2025, to June 30, 2025. This type of regular reporting on share repurchase/liquidity management activities, especially when detailing transactions, strongly aligns with the definition of 'Transaction in Own Shares' (POS). While it is a semi-annual report, the core subject is the management of the company's own shares via a liquidity contract, making POS more specific than a general Interim Report (IR) or Audit Report (AR).
2025-07-08 French
Affluent Medical : Bilan semestriel du contrat de liquidite contracte avec la banque Rothschild Martin Maurel
Regulatory Filings Classification · 95% confidence The document is titled "Affluent Medical : Bilan semestriel du contrat de liquidité contracté avec la banque Rothschild Martin Maurel" (Semi-annual report of the liquidity contract concluded with Rothschild Martin Maurel bank). It details the status of a liquidity contract (share holdings and transactions) as of June 30, 2025, covering the first half of 2025 (S1/2025). The AMF (Autorité des Marchés Financiers) category listed is "Information relative au contrat de liquidité" (Information relating to the liquidity contract). This specific type of disclosure, detailing transactions under a liquidity agreement, is not explicitly covered by the primary definitions (like 10-K, ER, IR). However, it is a mandatory regulatory disclosure concerning share activity and capital management, often falling under general regulatory announcements or specific capital/financing updates. Since it is a report on share transactions related to market stabilization/liquidity provision, it is most closely related to share activity or general regulatory filings. Given the options, 'Transaction in Own Shares' (POS) covers share buybacks/issuance, which is related but this is specifically about a liquidity contract. 'Capital/Financing Update' (CAP) is plausible but less precise. 'Regulatory Filings' (RNS) is the best fit as a specific regulatory disclosure that doesn't match the other detailed categories, especially since it's a periodic report on a specific regulatory agreement (liquidity contract). The document is a full report/disclosure, not just an announcement of a report (Rule 2 does not apply). I will classify this as RNS as it is a specific regulatory filing concerning market operations/liquidity contracts.
2025-07-08 French

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.